Skip to main content
Full access
Letters to the Editor
Published Online: 1 November 2022

Distinguishing the Effects of Lead-Time Bias and Duration of Untreated Psychosis: Reply to Jonas et al.

Publication: American Journal of Psychiatry
To the Editor: We thank Dr. Jonas and colleagues for their interest in our study (1) regarding their own recent investigation concerning lead-time bias (2). Analysis of our prospective, 20-year follow-up study of first-episode psychosis had been completed, and preparation of our manuscript for submission to the American Journal of Psychiatry was at its final stage when their article appeared. As our study was not conceived or analyzed in relation to lead-time bias, our initially submitted manuscript did not include discussion of this putative effect. We received the comments of five reviewers, three of whom advised that we consider our findings vis-à-vis those of Dr. Jonas and colleagues in relation to lead-time bias, noting the attention generated by their article in the Journal in its Letters to the Editor section (see the Editorial accompanying our article [3]), with the opinion that our findings appeared inconsistent with such bias. This we were pleased to do, as elaborated further below.
In their article, Dr. Jonas and colleagues state, “If lead-time bias explains the observed effect [that longer DUP predicts poorer psychosocial outcome], DUP should be associated with psychosocial function only in the period surrounding first admission,” and illustrate in their Figure 1c that the lead-time bias hypothesis would predict this effect to diminish and then disappear during several years following first admission. Our findings indicate that this effect endures across a 20-year period following first admission and therefore appears inconsistent with lead-time bias in terms of the criterion that Dr. Jonas and colleagues themselves propose. In our article we considered putative biopsychosocial mechanisms. However, we agree that lead-time bias was not analyzed specifically in our study and share their aspiration that future studies should investigate this putative effect directly.
Regarding the issue of diagnosis, our study was conceived and analyzed on the basis of the “real-world” diversity of first-episode psychosis, distinct from a schizophrenia-centric perspective of psychotic illness. As described in our article, incorporating affective versus nonaffective psychosis among baseline variables did not materially influence the final statistical models. We note that 1) the most recent meta-analysis on relationships between DUP and outcome found that exclusion of studies involving affective psychosis left the findings from their inclusion to be essentially unaltered (4), and 2) in a recent exercise conducted by the editors of Schizophrenia Research, across multiple international experts in the field, one of the majority opinions on psychotic illness was the need not to study schizophrenia as a unitary construct (5).
We reiterate the critical importance of disentangling all of the relationships mentioned above and confronting the methodological complexities involved in so doing. While the work of Dr. Jonas and colleagues is a stimulus to this objective and has generated useful discussion, it should not detract from the fundamental paradigm of seeking to treat psychotic illness as soon after its onset as is practicable.

References

1.
O’Keeffe D, Kinsella A, Waddington JL, et al: 20-year prospective, sequential follow-up study of heterogeneity in associations of duration of untreated psychosis with symptoms, functioning, and quality of life following first-episode psychosis. Am J Psychiatry 2022; 179:288–297
2.
Jonas KG, Fochtmann LJ, Perlman G, et al: Lead-time bias confounds association between duration of untreated psychosis and illness course in schizophrenia. Am J Psychiatry 2020; 177:327–334
3.
Malla A: Reducing duration of untreated psychosis: the neglected dimension of early intervention services. Am J Psychiatry 2022; 179:259–261
4.
Howes OD, Whitehurst T, Shatalina E, et al: The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. World Psychiatry 2021; 20:75–95
5.
Tandon R, Keshavan M, Nasrallah H: Reinventing schizophrenia. Updating the construct. Schizophr Res 2022; 242:1–3

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 863 - 864
PubMed: 36317328

History

Published online: 1 November 2022
Published in print: November 01, 2022

Authors

Affiliations

Donal O’Keeffe, Ph.D.
DETECT Early Intervention in Psychosis Service, Dublin, Ireland (O’Keeffe, Clarke); School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland (Kinsella, Waddington); Jiangsu Key Laboratory of Translational Research and Therapy for Neuropsychiatric Disorders, Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China (Waddington); School of Medicine, University College Dublin, Ireland (Clarke).
Anthony Kinsella, M.Sc.
DETECT Early Intervention in Psychosis Service, Dublin, Ireland (O’Keeffe, Clarke); School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland (Kinsella, Waddington); Jiangsu Key Laboratory of Translational Research and Therapy for Neuropsychiatric Disorders, Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China (Waddington); School of Medicine, University College Dublin, Ireland (Clarke).
John L. Waddington, Ph.D., D.Sc.
DETECT Early Intervention in Psychosis Service, Dublin, Ireland (O’Keeffe, Clarke); School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland (Kinsella, Waddington); Jiangsu Key Laboratory of Translational Research and Therapy for Neuropsychiatric Disorders, Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China (Waddington); School of Medicine, University College Dublin, Ireland (Clarke).
Mary Clarke, M.D. [email protected]
DETECT Early Intervention in Psychosis Service, Dublin, Ireland (O’Keeffe, Clarke); School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland (Kinsella, Waddington); Jiangsu Key Laboratory of Translational Research and Therapy for Neuropsychiatric Disorders, Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China (Waddington); School of Medicine, University College Dublin, Ireland (Clarke).

Notes

Send correspondence to Prof. Clarke ([email protected]).

Competing Interests

The authors’ disclosures accompany the original article.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share